Molecular docking studies of curcumin natural derivatives with DNA topoisomerase I and II-DNA complexes

Interdisciplinary Sciences – Computational Life Sciences

Volumn 6, Issue 4, 2014, Pages 285-291

  Kumar, Anil ^a   Bora, Utpal ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI   (India)

Author keywords

autodock; cancer drug target; curcumin natural derivatives; DNA topoisomerases; molecular docking; polar interactions

Indexed keywords

AMINO ACID; CURCUMIN; DNA; DNA BINDING PROTEIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; PLANT EXTRACT; TOP1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANALOGS AND DERIVATIVES; BINDING SITE; CHEMISTRY; CURCUMA; DNA CLEAVAGE; DNA REPLICATION; HUMAN; METABOLISM; MOLECULAR DOCKING; NEOPLASMS; STRUCTURE ACTIVITY RELATION;

AMINO ACIDS; ANTIGENS, NEOPLASM; BINDING SITES; CURCUMA; CURCUMIN; DNA; DNA CLEAVAGE; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HUMANS; MOLECULAR DOCKING SIMULATION; NEOPLASMS; PLANT EXTRACTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84919446786     PISSN: 19132751     EISSN: 18671462     Source Type: Journal    
DOI: 10.1007/s12539-012-0048-6     Document Type: Article

References (24)

1. Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A.B., Aggarwal, B.B. 2008b. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett 267, 133–164.
2. Anand, P., Thomas, S.G., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B. et al. 2008a. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76, 1590–1611.
3. Baird, C.L., Gordon, M.S., Andrenyak, D.M., Marecek, J.F., Lindsley, J.E. 2001. The ATPase reaction cycle of yeast DNA topoisomerase II. Slow rates of ATP resynthesis and P(i) release. J Biol Chem 276, 27893–27898.
4. Beck, L.S., Deguzman, L., Lee, W.P., Xu, Y., Siegel, M.W., Amento, E.P. 1993. One systemic administration of transforming growth factor-beta 1 reverses ageor glucocorticoid-impaired wound healing. J Clin Invest 92, 2841–2849.
5. Belani, C.P., Doyle, L.A., Aisner, J. 1994. Etoposide: Current status and future perspectives in the management of malignant neoplasms. Cancer Chemoter Pharmacol 34, 1180–1126.
6. Champoux, J.J. 2000. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Ann, N.Y., Acad Sci 922, 56–64.
7. Champoux, J.J. 2001. DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem 70, 369–413.
8. Chow, K.C., Macdonald, T.L., Ross, W.E. 1988. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: Implications for mechanism of topoisomerase inhibition. Mol Pharmacol 34, 467–473.
9. Gellert, M. 1981. DNA topoisomerases. Annu Rev Biochem 50, 879–910.
10. Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T.M., Vokes, E.E., Ratain, M.J. 1997. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15, 1502–1510.
11. Kumar, A., Bora, U. 2011. In silico inhibition studies of NF-κB p50 subunit by curcumin and its natural derivatives. Med Chem Res. doi:110.1007/s00044-011-9873-0.
12. Lin, J.K. 2007. Molecular targets of curcumin. Adv Exp Med Biol 595, 227–243.
13. López-Lázaro, M., Willmore, E., Jobson, A., Gilroy, K.L., Curtis, H., Padget, K., Austin, C.A. 2007. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. J Nat Prod 70, 1884–1888.
14. Maheshwari, R.K., Singh, A.K., Gaddipati, J., Srimal, R.C. 2006. Multiple biological activities of curcumin: a short review. Life Sci 78, 2081–2087.
15. Martín-Cordero, C., López-Lázaro, M., Gálvez, M., Ayuso, M.J. 2003. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib Med Chem 18, 505–509.
16. Morris, G.M., Goodsell, G.S., Halliday, R.S., Huey, R., Hart, W.E. et al. 1998. Automated docking using Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19, 1639–1662.
17. Mosieniak, G., Sliwinska, M., Piwocka, K., Sikora, E. 2006. Curcumin abolishes apoptosis resistance of calcitriol-differentiated HL-60 cells. FEBS Lett 580, 4653–4660.
18. Osheroff, N. 1989. Effect of antineoplastic agents on the DNA cleavage/religation equlibrium of eukaryotic topoisomerase II: Inhibition of DNA religation by etoposide. Biochemistry 28, 6157–6160.
19. Robinson, H.M., Bratlie-Thoresen, S., Brown, R., Gillespie, D.A. 2007. Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193. Cell Cycle 6, 1265–1267.
20. Salerno, S., Da Settimo, F., Taliani, S., Simorini, F., La Motta, C., Fornaciari, G., Marini, A.M. 2010. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Curr Med Chem 17, 4270–4290.
21. Sanner, M.F. 1999. Python: a programming language for software integration and development. J Mol Graph Model 17, 57–61.
22. Staker, B.L., Hjerrild, K., Feese, M.D., Behnke, C.A. et al. 2002. The mechanism of topoisomerase I poisoning by a camptothecin analog. PNAS 99, 15387–15392.
23. Wang, J.C. 1985. DNA topoisomerases. Annu Rev Biochem 54, 665–697.
24. Wang, J.C. 2002. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 3, 430–440.